On March 30, 2026, ImmunityBio, Inc. amended a revenue interest purchase agreement, receiving $75 million for additional revenue interests with payments tiered from 5.625% to 12.50% of net sales, and a partial conversion of $25 million in debt into 4.6 million shares of stock.